RxDoctor Payments DataLook up a doctor →

Andrew Rubin, MD

Clinical Cardiac Electrophysiology · Rancho Mirage, CANPI 1629038021

Payments from drug & device makers

$563,096in general payments, 2019–2025

Across 707 payments — averaging $796.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$375K
  • Abbott$50K
  • Medtronic$47K
  • Johnson & Johnson$44K
  • E.r. Squibb & Sons, L.L.C.$15K
  • Boston Scientific$13K
  • plus $19K from 19 others

What the payments were for

  • Consulting fees$49,29636%
  • Speaking & faculty fees$71,00851%
  • Travel & lodging$3,9903%
  • Food & beverage$14,55810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$563,096 in reported general payments places this provider in the 90th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$555,176
Medicare patients
2,123
Services billed
11,979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban757$892,257
XareltoRivaroxaban323$405,994
JardianceEmpagliflozin189$246,987
EntrestoSacubitril/Valsartan87$120,626
FarxigaDapagliflozin Propanediol37$45,402
MultaqDronedarone Hcl15$25,176
Repatha SureclickEvolocumab18$23,257
Flecainide Acetate500$21,058
Praluent PenAlirocumab12$10,851
VascepaIcosapent Ethyl17$10,452
Nebivolol Hcl107$8,354
Atorvastatin Calcium748$8,175
Metoprolol Succinate532$7,603
PradaxaDabigatran Etexilate Mesylate20$7,038
Ezetimibe184$6,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$6,081$892,257757 claims
Johnson & JohnsonXarelto$43,829$405,994323 claims
NovartisEntresto$40$120,62687 claims
AstraZenecaFarxiga$9,120$45,40237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →